ReviewCancers2026
Mediterranean Diet Adherence Tools in Post-Treatment Breast Cancer Survivors: A Scoping Review of Measurement Approaches and Associated Outcomes.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNutrition is an important yet underexplored determinant of cancer survivorship outcomes. Emerging evidence suggests that greater adherence to the Mediterranean diet (MedD) is associated with improved health status, enhanced quality of life (QoL), and reduced mortality. However, evidence specifically targeting post-treatment breast cancer survivors remains limited, and substantial heterogeneity in MedD scoring tools and adherence thresholds restricts comparability across studies. This review aimed to (i) identify and characterise the tools used to assess MedD adherence in breast cancer survivors following completion of active treatment, including their components, scoring systems, and adherence thresholds; and (ii) map the range of health outcomes that have been examined in relation to MedD adherence in this population.
methodsA scoping review was conducted in accordance with PRISMA-ScR and Joanna Briggs Institute guidelines. PubMed, Embase, Scopus, Web of Science, and CINAHL were searched (2000-2026) for English-language intervention and observational studies reporting MedD adherence in adult female breast cancer survivors after treatment completion. Two reviewers independently extracted data, which were synthesised descriptively, including study characteristics, MedD scoring tools, adherence outcomes, and clinical, metabolic, and QoL findings. The methodological structure protocol of this scoping review was retrospectively registered in the Open Science Framework.
resultsTwenty studies (16 intervention, 4 observational; 16 non-overlapping cohorts; pooled n
conclusionsThis scoping review identified considerable heterogeneity in how MedD adherence is measured in breast cancer survivors, with ten different scoring tools identified across 20 studies. Although improvements in MedD adherence appear achievable, the evidence is limited by small sample sizes, heterogeneous assessment tools, and short intervention durations. Larger, standardised longitudinal studies are needed, particularly to determine whether MedD adherence influences cancer recurrence and survival, for which current evidence remains minimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.